A pilot study to assess the incidence of local oropharyngeal and laryngeal adverse effects of Advair Diskus [salmeterol/fluticasone propionate] 250/50 mcg BID as assessed by the development of laryngitis and oropharyngeal candidiasis in adults with mild persistent asthma
Latest Information Update: 02 Feb 2024
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Adverse reactions
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 05 Jul 2007 New trial record.